Literature DB >> 34084231

Immunohistochemical expression and prognostic significance of VEGF-C in well-differentiated thyroid cancer.

S Ceric1, T Ceric2, N Pojskic3, N Bilalovic4, J Musanovic5, E Kucukalic-Selimovic1.   

Abstract

CONTEXT: Neoangiogenesis and lymphangio-genesis are essential for the growth of tumor and progression of malignancy.
OBJECTIVE: The study examined the significance of VEGF-C expression in comparison to classical prognostic factors in differentiated thyroid carcinoma (DTC), as well as an independent prognostic marker in DTC.
DESIGN: The study included 81 patients with DTC allocated in two groups according to the type of cancer (follicular versus papillary) and then compared to expression of VEGF-C and clinicopathological features.
METHODS: Expression of VEGF-C was identified with anti-VEGF-C antibody using tris-EDTA buffer Antigen Retrieval Protocol. Each specimen was scored with a semi-quantitative score system (H-score).
RESULTS: The analysis of T staging system showed a linear correlation between the size of a tumor, expression of VEGF-C and recurrence of a disease, with a statistical significance (p < 0.0001). There was a clear and significant correlation between VEGF-C expression and T stage in patients with papillary carcinoma (p = 0.0294). Analysis of invasion of a surgical margin demonstrated significant positivity in patients with papillary thyroid cancers who expressed VEGF-C (p = 0.0207) indicating the worse prognosis of a disease. Also a statistically significant correlation was between VEGF-C and extrathyroid extension, indicating the worse prognosis (p = 0.0133) in papillary cancers. The level of VEGF-C expression was statistically significant in patients with papillary thyroid cancer (p = 0.039).
CONCLUSIONS: This study undoubtedly demonstrates that VEGF-C expression is an evident negative prognostic factor in patients with papillary thyroid carcinoma, along with the classic prognostic factors, such as a larger tumor size, tumor margin involvement, extrathyroid extension, i.e. local aggressiveness. ©by Acta Endocrinologica Foundation.

Entities:  

Keywords:  VEGF-C thyroid; angiogenesis; thyroid cancer

Year:  2020        PMID: 34084231      PMCID: PMC8126380          DOI: 10.4183/aeb.2020.409

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  19 in total

Review 1.  Current views on the function of the lymphatic vasculature in health and disease.

Authors:  Yingdi Wang; Guillermo Oliver
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

Review 2.  New insights into the molecular control of the lymphatic vascular system and its role in disease.

Authors:  Leah N Cueni; Michael Detmar
Journal:  J Invest Dermatol       Date:  2006-10       Impact factor: 8.551

3.  Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.

Authors:  M Klein; J M Vignaud; V Hennequin; B Toussaint; L Bresler; F Plénat; J Leclère; A Duprez; G Weryha
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.

Authors:  Katsuhiro Tanaka; Hiroshi Sonoo; Junichi Kurebayashi; Tsunehisa Nomura; Sumiko Ohkubo; Yutaka Yamamoto; Shigeru Yamamoto
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors.

Authors:  Chung J Hung; David G Ginzinger; Raza Zarnegar; Hajime Kanauchi; Mariwil G Wong; Electron Kebebew; Orlo H Clark; Quan-Yang Duh
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

6.  VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

Authors:  John S Rudge; Jocelyn Holash; Donna Hylton; Michelle Russell; Shelly Jiang; Raymond Leidich; Nicholas Papadopoulos; Erica A Pyles; Al Torri; Stanley J Wiegand; Gavin Thurston; Neil Stahl; George D Yancopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

7.  Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.

Authors:  Ala'eddin Jebreel; James England; Karen Bedford; Justin Murphy; Laszlo Karsai; Stephen Atkin
Journal:  Int J Exp Pathol       Date:  2007-08       Impact factor: 1.925

8.  Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.

Authors:  Sonja Šelemetjev; Ilona Ðoric; Ivan Paunovic; Svetislav Tatic; Dubravka Cvejic
Journal:  Am J Clin Pathol       Date:  2016-11-01       Impact factor: 2.493

9.  Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.

Authors:  J Kurebayashi; T Otsuki; H Kunisue; Y Mikami; K Tanaka; S Yamamoto; H Sonoo
Journal:  Jpn J Cancer Res       Date:  1999-09

Review 10.  Angiogenesis in Malignant Thyroid Tumors.

Authors:  Matvey Vladimir Sprindzuk
Journal:  World J Oncol       Date:  2011-01-01
View more
  3 in total

Review 1.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

2.  Relationship between vascular endothelial growth factor expression and thyroid stimulating hormone level in benign and malignant thyroid lesions.

Authors:  Deepak Bariya; Shashi Prakash Mishra; B R Akshay; Sweety Kumari; Rahul Khanna; Ram Niwas Meena
Journal:  J Family Med Prim Care       Date:  2022-06-30

3.  A Four-Gene Signature Associated with Radioresistance in Head and Neck Squamous Cell Carcinoma Identified by Text Mining and Data Analysis.

Authors:  Yongqian Zhang; Hongmin Wang; Feifei Wang; Wenhua Ma; Na Li; Changwen Bo; YingChun Zhao; Li He; Ming Liu
Journal:  Comput Math Methods Med       Date:  2022-09-27       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.